TCTR20221215006Unknown3 期
Safety and immunogenicity of the third COVID-19 vaccines booster dose in children (12-18 years) with completed 2 doses as recommended by the ministry of public health
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 Years 至 18 Years（—）
- 性别
- All
入选标准
- •1. Healthy adolecents (aged between 12-18 years) who have previously received two doses following the ministry of public health (official proof of vaccinations required).
- •2. Have received your second dose of COVID-19 vaccine more than 3 months.
- •3. Have or Have not previously had COVID-19 infection.
- •4. are not in immunocompromised states (chronic diseases or immunodeficiency disorder)
- •5. No oallergies to the vaccine components
- •6. Are available for follow-ups and blood draws
排除标准
- •1. Immunodeficiency status
- •2. Do not agree to participate
- •3. Severe coagulopathy
研究者
相似试验
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine in Thai population.After the third dose of the COVID-19 vaccine, the immune response in healthy volunteers who received 2 doses of COVID19 vaccine (CoronaVac or ChAdOx1) at least three months.COVID-19 vaccine, Third dose, ChAdOx1, coronavac, Sinovac, BNT162b2, SinopharmTCTR20210731004Chulabhorn Royal Academy5,520
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine via intradermal compare with intramuscular administration (Randomized controlled trial)The immune response after the third dose of the COVID-19 vaccine via intradermal administration in healthy volunteers.COVID-19 vaccine, Third dose, intradermal, ChAdOx1, coronavac, Sinovac, BNT162b2, mRNA1263, SinopharmTCTR20210731003Chulabhorn Royal Academy960
进行中（未招募）
不适用
Immunogenicity of the 3rd COVID-19 vaccine dose in Thai healthcare workers at Bamrasnaradura Infectious Diseases InstituteHealthcare workers who received two doses of SinovacCOVID-19 VaccineSARS-CoV-2AntibodyHealthcare WorkersAstraZenecaPfizerTCTR20211005001ational Research Council of Thailand (NRCT)170
已完成
Unknown
Immune response to a third COVID-19 vaccine dose in people with multiple sclerosis receiving B cell-depleting therapyImmunosuppressionCOVID-19 vaccinationNeurological - Multiple sclerosisInfection - Other infectious diseasesMultiple SclerosisACTRN12623001249640Royal Adelaide Hospital53
招募中
不适用
Pattern of antibody response after 3rd dose of COVID-19 vaccine booster among healthy volunteers.Healthy volunteerCOVID-19 Vaccinesadministration and dosageimmunologyTCTR20210831002akornping Hospital180